Picard Medical Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Rhea-AI Summary

Picard Medical (NYSE American: PMI) announced its management team will attend conferences during the week of the 44th Annual J.P. Morgan Healthcare Conference (JPM week) in San Francisco.

Planned appearances include an invite-only Lifeblood and Goodwin MedTech CEO-Only Forum on January 12, 2026 at the InterContinental, and one-on-one meetings at the LifeSci Advisors 15th Annual Corporate Access Event on January 14, 2026 at The Beacon Grand. Investors may request in-person meetings via LifeSci registration or by contacting the LifeSci representative Eric Ribner at eric@lifesciadvisors.com.

Key Figures

JPM healthcare week 44th Annual Week of the 44th Annual J.P. Morgan Healthcare Conference

MedTech CEO forum date January 12, 2026 Lifeblood and Goodwin’s MedTech CEO-Only Forum

Corporate access date January 14, 2026 LifeSci Advisors 15th Annual Corporate Access Event

Market Reality Check

$1.68 Last Close

Volume Volume 202,802 is 57% below the 20-day average of 471,854, indicating light trading ahead of conference participation. low

Technical Shares at $1.73 are trading ~36% below the 200-day MA of $2.71 and 87.35% below the 52-week high of $13.68.

Peers on Argus

PMI gained 3.59% with light volume while peers were mixed: CTKB up 6.15%, KIDS up 4.69%, LAB down 2.31%, AVMR and ZIMV flat. Moves do not indicate a unified sector trend.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 30	Management/board update	Positive	-6.4%	CEO elected to Arizona Bioindustry Association board through December 2028.
Dec 24	Debt financing	Negative	-1.9%	Announcement of up to $50M senior secured notes and warrants for funding.
Dec 18	Listing milestone	Positive	+10.3%	Company marked NYSE opening bell to highlight transition to public markets.
Dec 09	Clinical durability update	Positive	-8.7%	Patient surpassed 2,900 days supported by SynCardia Total Artificial Heart.
Dec 03	Conference presentation	Positive	+2.0%	CEO scheduled to present Emperor Total Artificial Heart data at CSI Focus D-HF.

Pattern Detected

Recent news shows mixed alignment: positive milestones sometimes saw gains, but several upbeat or neutral announcements were followed by declines, indicating inconsistent reactions to corporate updates.

Recent Company History

This announcement focuses on PMI’s participation in investor and MedTech forums during J.P. Morgan Healthcare Conference week, continuing a pattern of visibility events following its NYSE opening-bell milestone on December 18, 2025. In recent months PMI highlighted long-term patient support with its SynCardia Total Artificial Heart, early Emperor Total Artificial Heart data and presentations, and governance visibility via its CEO’s AZBio board election. Financing actions included up to $50.0 million senior secured notes and earlier bridge funding, underscoring ongoing capital needs alongside technology and profile-building efforts.

Market Pulse Summary

The stock surged +10.4% in the session following this news. A strong positive reaction aligns with PMI’s efforts to raise visibility during major healthcare investor gatherings, including J.P. Morgan Healthcare Conference week and related MedTech forums. Historically, some milestones, such as the NYSE opening-bell event, were followed by gains, while other positive updates saw selling. Investors have also seen recent secured-note financing and a going concern warning in filings, factors that could influence how sustainable a move above recent levels might be if enthusiasm fades.

Key Terms

total artificial heart medical

"maker of the world’s first total artificial heart approved by both the U.S."

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

u.s. food and drug administration regulatory

"artificial heart approved by both the U.S. Food and Drug Administration (FDA) and"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

fda regulatory

"artificial heart approved by both the U.S. Food and Drug Administration (FDA) and"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

health canada regulatory

"approved by both the U.S. Food and Drug Administration (FDA) and Health Canada today"

Health Canada is the government department responsible for overseeing the safety and regulation of health-related products and services in Canada, including medications, medical devices, and vaccines. Its approval and guidelines help ensure that these products are safe and effective for public use. For investors, Health Canada's decisions can influence the success of healthcare companies and affect the availability of new medical treatments in the Canadian market.

AI-generated analysis. Not financial advice.

TUCSON, Ariz., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems, LLC, maker of the world’s first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada today announced that today announced its attendance at conferences during the week of the 44^th Annual J.P. Morgan Healthcare Conference (“JPM week”) including at LifeSci Advisors’ Corporate Access Event and Lifeblood and Goodwin’s CEO-Only MedTech Forum.

Information on both events is below.

Lifeblood and Goodwin’s MedTech CEO-Only Forum
Date: January 12, 2026
Format: Invite-only discussion forum
Location: InterContinental, San Francisco, CA

LifeSci Advisors 15^th Annual Corporate Access Event
Date: January 14, 2026
Format: One-on-one meetings
Location: The Beacon Grand, San Francisco, CA

To request an in-person meeting with the Picard Medical management team on Wednesday January 14^th, either register at LifeSci Partners Corporate Access Event 2026 or contact our LifeSci Partners representative Eric Ribner (eric@lifesciadvisors.com).

About Picard Medical, Inc.
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For more information, please visit https://www.syncardia.com.

Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

When will Picard Medical (PMI) attend JPM week events in 2026?

Picard Medical indicated management will attend events during JPM week, including January 12 and January 14, 2026.

Which Picard Medical events are scheduled for January 12 and January 14, 2026?

An invite-only Lifeblood and Goodwin MedTech CEO-Only Forum on January 12, 2026, and LifeSci Advisors one-on-one meetings on January 14, 2026.

Where will Picard Medical meet investors during JPM week 2026?

The January 12 forum is at the InterContinental, San Francisco, and January 14 meetings are at The Beacon Grand, San Francisco.

How can investors request an in-person meeting with Picard Medical (PMI) on January 14, 2026?

Register at the LifeSci Partners Corporate Access Event 2026 or contact LifeSci representative Eric Ribner at eric@lifesciadvisors.com.

Is the Picard Medical JPM week participation open to the public?

The MedTech CEO-Only Forum on January 12 is invite-only; the January 14 LifeSci meetings are scheduled as one-on-one sessions requiring registration or a contact.